Alpha Cognition (ACOG) versus The Competition Head-To-Head Review

Alpha Cognition (NASDAQ:ACOG) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Alpha Cognition to related companies based on the strength of its analyst recommendations, profitability, earnings, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Alpha Cognition and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Earnings and Valuation

This table compares Alpha Cognition and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-1.98
Alpha Cognition Competitors	$574.62 million	-$70.96 million	0.09

Alpha Cognition’s peers have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 31.5% of Alpha Cognition shares are held by company insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Alpha Cognition has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s peers have a beta of -3.86, indicating that their average share price is 486% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Alpha Cognition and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1924	5385	13933	296	2.59

Alpha Cognition currently has a consensus price target of $20.00, suggesting a potential upside of 295.26%. As a group, “Biological products, except diagnostic” companies have a potential upside of 108.79%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, analysts clearly believe Alpha Cognition is more favorable than its peers.

Summary

Alpha Cognition beats its peers on 8 of the 13 factors compared.

Alpha Cognition Company Profile

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.